Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

Fig. 2

Mutations in ARID1 subunits predict an improved prognosis for cancer immunotherapy. a The different percentages of patients who responded (complete response+partial response+stable disease) to immune checkpoint inhibitors (ICIs) grouped by the genomic signatures of ARID1 subunits; b. The different progression-free survival (PFS) times grouped by the genomic signatures of ARID1 subunits; c. The survival curves for ICIs-treated patients based on the genomic signatures of ARID1 subunits. (*: P<0.05.)

Back to article page